NL0015436031 - Common Stock
CUREVAC NV
NASDAQ:CVAC (10/4/2024, 8:12:54 PM)
After market: 2.99 -0.03 (-0.99%)3.02
+0.06 (+2.03%)
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 999 full-time employees. The company went IPO on 2020-08-14. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076
P: 49707198830
CEO: Franz-Werner Haas
Employees: 999
Website: https://www.curevac.com/
CVAC stock results show that CureVac missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on CVAC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: